Germany Pharmaceuticals 6 Mar 24 – INDUSTRY SNAPSHOTS
BNN Breaking -
For the complete story see:
Reuters - Bayer purchases heart drug for up to
Bayer opens new tab said on Monday it acquired the exclusive marketing rights for
For the complete story see:
CHEManager - Merck Opens New €20 Million Distribution Center in
Merck will open a new € 20 million distribution center in
For the complete story see:
https://www.chemanager-online.com/en/news/merck-opens-new-eu20-million-distribution-center-brazil
Other Stories
Pharmaceutical Technology - Bayer wins FDA breakthrough therapy designation for NSCLC candidate -
The Pharma Letter - Boehringer's dual-action GLP-1 agonist hits goals in MASH trial -
BNN Breaking - Fresenius Medical Care Forecasts Robust Earnings Growth Amidst Global Dialysis Demand Surge -
Media Releases
Bayer - Bayer strengthens pharma portfolio with new cardiology drug acoramidis -
Bayer -
Merck - Merck Opens new € 20 Million Distribution Center in
CXCR5 is a very promising drug target for the development of antibody-drug conjugates to treat patients with lymphoma - By
Industry Overview
The Pharmaceutical Industry
Overviews of Leading Companies
B.
Grünenthal
Rhön-
Associate:
News and Commentary
BNN Breaking -
For the complete story see:
Reuters - Bayer purchases heart drug for up to
Bayer opens new tab said on Monday it acquired the exclusive marketing rights for
For the complete story see:
CHEManager - Merck Opens New €20 Million Distribution Center in
Merck will open a new € 20 million distribution center in
For the complete story see:
https://www.chemanager-online.com/en/news/merck-opens-new-eu20-million-distribution-center-brazil
Pharmaceutical Technology - Bayer wins FDA breakthrough therapy designation for NSCLC candidate -
The
For the complete story see:
German pharma group finds no unexpected side effects during trial, including at higher doses.
For the complete story see:
https://www.ft.com/content/0a75f311-f960-4f81-9c11-00e14923ecef
The Pharma Letter - Boehringer's dual-action GLP-1 agonist hits goals in MASH trial -
For the complete story see:
BNN Breaking - Fresenius Medical Care Forecasts Robust Earnings Growth Amidst Global Dialysis Demand Surge -
For the complete story see:
German pharma and lab supplier Sartorius reported that fiscal 2023 profit to equity holders of
For the complete story see:
https://news.yahoo.com/german-pharma-lab-supplier-sartorius-104150101.html
Media Releases
Bayer - Bayer strengthens pharma portfolio with new cardiology drug acoramidis -
Acquisition of exclusive commercialization rights for European markets / Highly potent selective small molecule oral transthyretin stabilizer for transthyretin amyloid cardiomyopathy (ATTR CM) / Marketing authorization application already submitted to
Marketing authorization application (MAA) with the
"Bayer has a clear vision to transform cardiovascular care for patients and acoramidis complements our portfolio in specialty cardiology," said
"We are excited to have found a like-minded partner in Bayer that shares our belief in the potential of acoramidis to ameliorate the lives of ATTR CM patients. We have a responsibility to the ATTR CM community to make acoramidis available to as many patients as possible, as quickly as possible, and we believe that Bayer is the right collaborator for us in this mission," said
Under the terms of the agreement, BridgeBio and the affiliates will receive up to
Bayer -
Leverkusen,
"We are extremely pleased to have
Triana is married with one son and in addition to his native country,
Merck - Merck Opens new € 20 Million Distribution Center in
13,000 square-meters space for Life Science business sector accommodates 11,000 pallet positions and more than 50,000 stock-keeping units
New site in Cajamar, São Paulo has 2.5 times more storage capacity than previous space in Cotia, São Paulo
13,000 square-meters space for Life Science business sector accommodates 11,000 pallet positions and more than 50,000 stock-keeping units
Employees from Cotia will move to Cajamar distribution center
Merck, a leading science and technology company, will open a new, € 20 million distribution center in Cajamar,
According to Vinícius Andremarchi, Head of Distribution for Life Science at Merck,
"In 2023, the pharmaceutical industry and academic markets in
The layout of the new space makes it possible to optimize workflows and has more technological equipment and automated, ergonomic workstations for employees. Other features include a 1,000m² mezzanine, laboratories, administrative rooms, employee amenities and customer reception.
The new site is closely alignment with Merck's global sustainability objectives: With a well-designed environment, the space has received the Leadership in Energy and Environmental Design (LEED) Gold level certification from the
https://www.merckgroup.com/en/news/new-distribution-center-in-brazil-27-02-2024.html
CXCR5 is a very promising drug target for the development of antibody-drug conjugates to treat patients with lymphoma
Abstract
Introduction: The chemokine receptor CXCR5 is highly expressed in tumor cells from different lymphoma types and represents a viable drug target for the development of antibody-drug conjugates (ADC) to treat patients with lymphoma.
Methods: Immunohistochemistry of human tissues of different lymphoma types were stained using antibodies against human CXCR5, CD20, CD70 and CD79b. Slides were examined by a pathologist and scored for expression. CXCR5 expression on tumor cell lines was analyzed by flow cytometry. Cell surface receptor density was analyzed by Quantibrite ™ PE-beads. Evaluation of antibody internalization was performed using the Operetta High Content Imaging System. NOD/SCID mice were transplanted subcutaneously with lymphoma patient-derived (PDX) tumor specimens and treated with 2mg/kg or 10mg/kg VIP924 CXCR5-ADC or isotype control.
Results: CXCR5 reveals very low to no expression in most tissues except for lymph nodes. Expression of CXCR5 and other B-cell targets like CD19, CD20, CD70 and CD79b was analyzed on patient-derived tumor samples. High expression of CXCR5 was found on naïve and previously treated diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), mantle cell lymphoma (MCL), and chronic lymphocytic leukemia (CLL) samples. Based on these results, we developed a CXCR5 targeted ADC with a novel, highly potent kinesin spindle protein inhibitor (KSPi) payload linked via a legumain-cleavable linker (VIP924). To compare the performance of KSPi ADCs, the same effector chemistry was attached to antibodies against other B-cell targets and tested in cytotoxicity assays in various cell lines. CXCR5-targeted ADC demonstrates significantly higher activity compared to the other ADCs tested except for the CD79b ADC with equal potency. VIP924 was then tested in vivo in different PDX tumor mouse models with different levels of CXCR5 expression. In the LY2264 and HBL-1 DLBCL models, we obtained a tumor growth inhibition of 68% and 100% respectively compared to isotype control. The median survival time for the isotype control group was 29 days and median survival time for the mice treated with 10mg/kg VIP924 could not be determined as all mice survived until the end of the study (Day 37). No effect on body weight or any adverse effects in the VIP924 treated mice were observed.
Conclusions: CXCR5 is a highly attractive target in hematological malignancies such as DLBCL, MCL, and FL due to high protein expression and almost no expression in healthy tissues. CXCR5-targeting ADC with KSPi payload showed high potency and superiority to other B-cell-targeted ADCs in vitro on a broad range of lymphoma cell lines. VIP924 with a novel legumain-cleavable linker showed activity in in vivo PDX models from lymphoma patients. Due to the high CXCR5 expression found in relapsed DLBCL patients, VIP924 may bring promising new treatment options for previously treated patients with lymphoma.
Citation Format:
https://aacrjournals.org/cancerres/article/83/7_Supplement/6294/721035
The Industry
INDUSTRY OVERVIEW
The Pharmaceutical Industry in
"
5.1% annual revenue growth in the pharmaceutical market (pharmacies and clinics) over a five- year period (CAGR 2014-2019)
12.5% of revenue invested in R&D in 2018 - the highest rate among all major industry sectors in
83 mln population drives domestic demand for health- care products and services
Combining cutting edge innovation, a long tradition as the "world´s pharmacy" and continuously growing demand for healthcare products,
The country is the largest exporter of medicinal products and ranks among the top pharmaceutical producers worldwide. In light of the global need for personalized medicine,
The Pharmaceutical Industry in Numbers
Strong Industry Base
More than 500 pharmaceutical companies are located in
Leading Pharmaceutical Supplier
Following its tradition as the "world's pharmacy,"
R&D Excellence and Innovation
Market Opportunities & Trends
Growing Healthcare Market
With 83 million inhabitants,
Demographic Change
One of the main drivers of the healthcare market is demographic change.
Chronic Diseases
The treatment of the growing number of patients affected by (age-related) chronic and incommunicable diseases constitutes a major concern of the German healthcare system. Together, cardiovascular diseases, psychological disorders and musculoskeletal diseases account for more than one third of overall healthcare spending in
Mandatory health insurance and different sources of financing contribute to solid healthcare provision including access to medicines - in
"Out-of-Pocket" Payments
Increasingly, patients are also paying for medicines "out-of-pocket", mainly for over-the-counter medicines and co-payments for prescribed drugs. This trend is also driven by so-called "switches", meaning that previous prescription-only medicines gain the non-prescription status. This was the case for 25 treatments between 2007 and the beginning of 2020. In the light of growing health- care expenses, self-medication and consultation provided by local pharmacies may also relieve doctors and health insurers.
Over-the-Counter (OTC) Market
Market Trends
Market Segments
The German OTC market comprises two major segments: non-prescription drugs and health products. Non prescription drugs include pharmacy-only drugs as well as OTC drugs that may also be sold outside of pharmacies. Product groups that are not subject to pharmaceutical legislation for example, nutritional supplements, healing earths and seawater nasal sprays belong markets. The average annual growth rate of the German OTC market amounts to four percent for the period 2014 to 2019. In 2019, revenues increased by 3.7 percent to almost
Opportunities
Remedies for the respiratory system and pain treatments account for the highest share of overall OTC sales via pharmacies (including mail order). In 2019, the vitamins and minerals seg- ment demonstrated the highest growth rate (6.8 percent), with revenue exceeding
Biopharmaceuticals
Increasing Market Share
The development of biological drugs has led to substantial shifts in the pharmaceutical industry landscape in recent years. Large companies have moved their focus from small molecule drugs towards the development and production of complex biological compounds that are made with the help of a variety of organisms. Because of their high therapeutic potential, biologics have taken up a considerable share of the pharmaceutical market in
Market penetration has been steadily increasing in recent years, but differs according to therapeutic area. Biopharmaceuticals generate 80 percent of immunology sales, whereas the figure is as low as three percent for cardiovascular indications. Biopharmaceutical sales in oncology grew by 23 percent in 2019, but the highest growth rate was recorded by anti-infective with an increase of 40 percent.
Development Pipeline
The growing importance of biopharmaceuticals is also reflected in the development pipeline. As of 2019, companies active in pharma R&D in
Biosimilars
As innovative biological drug patents expire, more pharma companies have the opportunity to manufacture and commercialize the compound - a key factor in pharma market dynamics in recent years.
Pharma Manufacturing
Major Production Location
Contract Manufacturing Organizations
High Production Standards
Investment and Trade
The investment activity of pharmaceutical companies in
Research Excellence
Research Landscape
Over 30 biotechnology clusters contribute substantially to the advancement of pharmaceutical innovation by bundling scientific expertise as well as connecting academic and industrial players in the field of drug development. In addition to the over 400 universities in
In order to foster the translation of research out- comes into successful products, the Go-BIO pro- gram supports biotechnology start-ups in bringing their inventions to market. Since 2005, 58 newly established biotech companies have received support to grow into sustainable businesses. The Life Science Incubator (LSI) in Bonn and Dresden also helps scientists to bridge the critical gap between a good idea and the proof of concept, making further financing opportunities available. Moreover, the LSI supports academics with out- standing business ideas by providing them with the entrepreneurship expertise required for their value proposition to take off.
Over 15 start-up centers specifically dedicated to fostering emerging biotech/life science companies can be found all over
The pharmaceutical industry is known for its high R&D intensity - and
Clinical Research
Thanks to its high population,
Business Location Germany
Top Investment Location
Sound and Secure Legal Framework
The legal framework for FDI in
Business-friendly Tax Conditions
World-class Infrastructure
With state-of-the-art transportation networks (road, rail, sea, and inland waterways) as well as a dense network of national and international airports,
Competitive Labor Costs
High productivity rates and steady wage levels make
Highly Skilled and Motivated Workforce
Dual Education System
In order to secure the economy's demand for highly qualified personnel and to meet industry needs,
Between 2015 and 2017,
Takeda - Providing a Production Advantage
Takeda is a global biopharmaceutical company headquartered in
"
Heidrun Irschik-Hadjieff
Takeda has invested more than
Source: GTAI
https://www.gtai.de/gtai-en/invest/industries/life-sciences/pharmaceuticals
Leading Companies
The parent company of the global
The
Aenova is one of the leading contract manufacturers in
Aenova provides a full service for customers from industry and commerce that covers everything from product development, raw material procurement, production, and analytics right up to packaging and logistics.
High standards of quality, innovative technologies, and a clear focus on the future ensure the continuing success and dynamic growth of the Group. We make long-term investments in the development of new products and the improvement of our production processes. At the same time, we are able to flexibly and rapidly react to changing requirements from customers and markets. Thanks to this strategy, Aenova ensures its long-term competitiveness and continuously increases its market share.
The Group operates 22 sites in eight European countries,
https://www.aenova-group.com/en/competence-crucial
The
Starnberg,
The
The key figures 2022 of Aenova at a glance:
€ 749 million
€ 107 million adjusted EBITDA
+ 22% Order book
"We continued to expand our capacities to allow for future growth and continue to grow our technology offering to increase our competitiveness in the market," said Jan Kengelbach, CEO of
Despite an increased revenue by +7.5% from
from
Learn more about Aenova's 2022 achievements and milestones, as well as key events in each business unit.
The parent company of the global
Bayer is a Life Science company with a more than 150-year history and core competencies in the areas of health care and agriculture. With our innovative products, we are contributing to finding solutions to some of the major challenges of our time.
The Pharmaceuticals division focuses on prescription products, especially for cardiology and women's healthcare, and on specialty therapeutics in the areas of oncology, hematology and ophthalmology. The division also comprises the radiology business, which markets diagnostic imaging equipment together with the necessary contrast agents.
The Crop Science division is a world-leading agriculture enterprise with businesses in seeds, crop protection and nonagricultural pest control. The Crop Protection / Seeds operating unit markets a broad portfolio of high-value seeds and innovative pest management solutions, while at the same time providing extensive customer service for sustainable agriculture. The Environmental Science operating unit provides products and services for professional nonagricultural applications, such as vector and pest control and forestry.
https://www.bayer.com/en/profile-and-organization.aspx
Second quarter impacted by declines in glyphosate business
Group sales fall by 8.2 percent (Fx & portfolio adj.) to
Leverkusen,
Group sales declined by 8.2 percent (Fx & portfolio adj.) to
Free cash flow amounted to minus
Crop Science sales without glyphosate at prior-year level (Fx & portfolio adj.)
Sales in the agricultural business (Crop Science) fell by 18.5 percent (Fx & portfolio adj.) to
EBITDA before special items at Crop Science fell by 58.5 percent to
Pharmaceuticals: new products deliver substantial growth
Sales of prescription medicines (Pharmaceuticals) came in at
EBITDA before special items at Pharmaceuticals declined by 6.7 percent to
Sales of self-care products (
EBITDA before special items at
Group outlook lowered on
With respect to the divisions, the company now expects Crop Science sales to fall by around 5 percent year on year (initial forecast: increase by around 3 percent) and Pharmaceuticals sales to show a roughly 0 percent change against the prior-year level (initial forecast: increase by approximately 1 percent) after adjusting for currency and portfolio effects. The currency-adjusted EBITDA margin before special items is now projected to come in at around 21 percent at Crop Science (initial forecast: 25 to 26 percent) and approximately 28 percent at Pharmaceuticals (initial forecast: slightly above 29 percent). The forecast for
Forward-Looking Statements
This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer's public reports which are available on the Bayer website at
www.bayer.com
. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.
https://www.bayer.com/media/en-us/second-quarter-impacted-by-declines-in-glyphosate-business/
B.
The parent company of the global
True partner. Smart solutions. Set standards.
As one of the world's leading medical technology companies, B. Braun aims to protect and improve the health of people around the world. For more than 180 years, we have shaped health care with our pioneering spirit and groundbreaking contributions.
https://www.bbraun.com/en/about-us/company.html
B. Braun closes 2022 fiscal year with sales growth - result burdened
"2022 was a difficult year in which B. Braun was strongly challenged," said B. Braun CEO
"But we were able to continue our growth in a persistently volatile market through special dedication and reliably supplied products and services to our customers. Particularly now, when pressure on health care systems continues to increase, at B. Braun we are aware of our special responsibility and are working hard to provide quality health care to more people around the world together with our customers."
B. Braun's sales were positive in nearly every region and across broad segments of its portfolio. Sales fell for some products that were in very high demand during the coronavirus pandemic but saw less demand in FY 2022. Hospital Care benefited overall from stable volumes and price adjustments caused by inflation. The surgical division Aesculap recovered from the significant burdens caused by the pandemic in 2020 and 2021, as more elective surgeries were performed worldwide. Demand steadily increased, especially for knee and hip implants as well as surgical instruments and suture materials. Avitum could not recapture the increased sales in the infection prevention business seen during the pandemic, but sales improved in the therapeutic areas of extracorporeal blood treatment as well as wound management, ostomy care and continence care.
"We're not satisfied with the earnings situation," said Braun. "It's even more important that we took prompt corrective action, early in the reporting year to improve our profitability. This allowed us to stabilize our result, even if price increases and cost reductions couldn't completely compensate for the negative effects. At B. Braun we will continue to consistently adjust our collaborations, our structures and business models to the changing world this fiscal year—our goal remains meeting customer needs even more quickly and with greater flexibility, and to drive advancements in health care."
B. Braun continues to invest in the future
Global measures to stabilize the result allowed B. Braun to continue to invest during FY 2022. A total of over
Consistently pursuing strategy in a difficult market environment
In order to continue to operate successfully as a private, family-owned company, B. Braun took a critical look at its productivity, structures and processes in the reporting year. The company's goal is to continue to standardize, digitalize and simplify processes under its B. Braun—the next decade strategy. Appropriate changes and more efficient collaboration resulted in the number of B. Braun employees decreasing to 65,055 (previous year: 66,778) as of
New possibilities through technology and sustainability
In health care, new technologies offer possibilities for treating people around the world using the highest medical standards, while also ensuring the affordability of care through better efficiency. This also motivated B. Braun in FY 2022 to make innovative solutions accessible to customers, patients, and a wider health care industry. The company offers high-quality product systems enabled by technologies it continues to refine. One example is B. Braun's Spaceplus infusion pump system, which can be connected to hospital data management systems. Infusion data is automatically transmitted and made accessible to medical staff for patient treatment. In the operating room, our Aesculap Aeos® robot-assisted surgical microscope deploys the latest imaging techniques, setting new benchmarks for depth of field, field of view and lighting. (www.bbraun.com/view-of-the-future)
B. Braun also employs technological developments to weave sustainability through its supply chains, production and logistics processes, and resource management. The company continued to improve its sustainability structures to attain a competitive edge through professional sustainability management for the future. One example is B. Braun's dialysis equipment, which conserves resources and improves processes by using less water, energy, and materials. (www.bbraun.com/dialysis-is becoming-green)
Outlook
B. Braun expects positive sales and results in FY 2023. The company also expects the current high prices for raw materials, energy, and logistics services to continue over the short and medium term. In response, in 2023 B. Braun will continue to reinforce the structural changes started in 2022. The contribution to profit expected from these changes should offset cost increases and continue to improve profitability.
The parent company of the global
Making new and better medicines for humans and animals is at the heart of what we do. Our mission is to create breakthrough therapies that change lives. Since its founding in 1885,
As a world-leading, research-driven pharmaceutical company, more than 51,000 employees create value through innovation daily for our three business areas: Human Pharma,
We realize more scientific opportunities by embracing the power of partnership and diversity of experts across the life-science community. By working together, we accelerate the delivery of the next medical breakthrough that will transform the lives of patients now, and in generations to come.
https://www.boehringer-ingelheim.com/
https://www.boehringer-ingelheim.com/corporate-profile/our-company
First half of 2023:
Ingelheim,
Areas of progress include rare skin diseases, cardio-renal-metabolic diseases, and immuno-oncology
Jardiance® and NexGard® portfolios drive strong growth
First half 2023 net sales up 9.7 percent at
Currency-adjusted net sales rose by 9.7 percent to
"True innovation addressing high unmet patients' needs has enabled us to reach ever more patients in the first half of this year," said
Net sales in Human Pharma were up 11.3 percent (currency-adjusted) at
Jardiance® experienced strong momentum in the first six months of 2023. It is expected to grow following additional regulatory action for treatment of chronic kidney disease. Worldwide 850 million people1 live with this disease. With the addition to existing indications in type 2 diabetes and heart failure, Jardiance® will potentially be able to help manage cardio-renal-metabolic conditions. Over 1 billion people live with cardio-renal-metabolic conditions globally1.
In oncology, the company's MDM2-p53 agonist brigimadlin has advanced into the pivotal trial for the treatment of dedifferentiated liposarcoma, a rare cancer with limited treatment options so far. The clinical development of two additional investigational therapies (zongertinib, also known as BI 1810631, and BI 764532) from the oncology pipeline has been accelerated based upon positive early clinical data.
The PDE4B inhibitor BI 1015550 is now in two clinical Phase III trials for the treatment of Idiopathic Pulmonary Fibrosis (IPF) and Progressive Pulmonary Fibrosis. Patient recruitment for trial investigating BI 1015550 in IPF is well ahead of plan.
"We have become very successful in bringing new products through our pipeline addressing patients' needs faster," said
In addition, the company complemented its market-leading NexGard® portfolio through FDA approvals for NexGard® PLUS, a new monthly combination product for dogs that protects against fleas, ticks, heartworm disease, roundworms and hookworms, and NexGard® COMBO, the first-and-only feline broad-spectrum parasite protection that treats tapeworms.
For the remainder of the year
Looking forward, the company aims to achieve more than 30 new medical approvals in Human Pharma by 2029 and expects around 20 product launches in
The parent of the global
Under the umbrella of the TecDAX-listed company
The
We supply and provide
innovative technologies and application-oriented solutions designed to help doctors improve their patients' quality of life
complete packages of solutions for the diagnosis and treatment of ophthalmic diseases, including implants and consumables
innovative visualization solutions in the field of microsurgery
promising, future-oriented technologies such as intraoperative radiotherapy.
Therefor we are guided by our Mission to uniquely enable healthcare professionals worldwide to improve the lives of their patients in ophthalmology, microsurgery and other medical growth sectors and advance the standards of care with our proven medical technology and application competence. Together with our colleagues at sites all over the world, we work to achieve this goal on a daily basis.
https://www.zeiss.com/meditec-ag/about-us.html
The Group's head office is located in Jena,
https://www.zeiss.com/meditec/int/news.html
Decline in profit due to expected weaker product mix
Jena,
Dr.
Revenue growth primarily boosted by equipment business and SBU Microsurgery
Revenue in the Ophthalmic Devices strategic business unit (SBU) decreased by -2.0% in the first three months of fiscal year 2023/24 (adjusted for currency effects: 0.0%), to €351.1m (prior year: €358.2m). In particular the planned reduction of stocks of consumables for refractive surgery in the Chinese distribution channel had an adverse effect. Currency effects also had a negative impact.
The strategic business unit Microsurgery achieved revenue growth of +10.6% (adjusted for currency effects: +13.7%) to €123.9m (prior year: €112.0m). The SBU continued to benefit from the reduction of the high order backlog.
Heterogeneous sales development in the reporting regions
Revenue in the EMEA 1 region increased by +28.2% (adjusted for currency effects: +30.9%) to €156.5m (prior year: €122.1m). The core markets
Revenue in the
The APAC 2 region recorded a slight decline in revenue of -0.9% (adjusted for currency effects: +0.4%), to €206.4m (prior fiscal year: €208.2m).
Operating result down compared with prior year, as expected
The operating result (earnings before interest and taxes, EBIT) declined in the first quarter of fiscal year 2023/24, to €43.5m (prior year: €60.3m). As expected, gross profit came under considerable pressure due to a less favorable product mix - resulting from a higher proportion of devices and a lower proportion of consumables due to the reduction of stocks in the Chinese distribution channel.
The EBIT margin in the first three months of fiscal year 2023/24 was 9.2% (prior year: 12.8%). Adjusted for special effects, this figure was 9.7% (prior year: 13.4%). Earnings per share benefited from gains on currency hedges and amounted to €0.42 in the first quarter (prior year: €0.57).
Outlook for the further course of business in 2023/24
In spite of geopolitical risks and an increasingly difficult macroeconomic environment, the Company generally expects to see further market growth. Revenue is expected to grow at least in line with the market growth. A gradual recovery of the EBIT margin is expected in the further course of the year. EBIT for fiscal year 2023/24 as a whole is expected to be around the prior year's level.
All figures in €m
3 months 2023/24
3 months 2022/23
Change from prior year
Change from prior year (currency-adjusted)
Ophthalmology
351.1
358.2
-2.0%
0,0%
Microsurgery
123.9
112.0
+10.6%
+13.7%
Consolidated
475.0
470.3
+1.0%
+3.3%
https://www.zeiss.com/meditec-ag/en/media-news/press-releases/2024/interim-report-q1-fy-2023-24.html
The company
is active on international (
The optimisation of pharmacotherapy through continuous development and in cooperation with other future-oriented companies, e.g. diseases of the central nervous system, is one of Desitin's main areas of activity and investment.
Ongoing training and scientific information as well as cooperation with the treating physicians and centres are our company's further contribution to long-term treatment success for neurological-psychiatric illnesses.
We regard ourselves as a partner for physicians, pharmacists and patients as well as their families and provide extensive service as product support. Our highly specialised field staff as well as our medical employees provides the physicians with expert and competent assistance.
We also regard ourselves as advocates to patients suffering from epilepsy and Morbus Parkinson in order to protect them from negative effects on their diagnosis and treatment during changes in public health care. In this regard we seek and find dialogue with cost carriers and health ministers in order to increase their understanding of the special requirements of these CNS illnesses.
https://www.desitinpharma.com/about-desitin/the-company/
https://www.desitinpharma.com/portal/
Desitin is focused on pharmaceuticals for the treatment of epilepsy. It is the only manufacturer that offers the entire spectrum of products recommended by the WHO for the treatment of epilepsy.
Desitin not only offers a wide range of different therapeutics, but also a broad spectrum of presentations and dosage strengths.
Whereas most of these preparations have been developed inhouse by Desitin and successfully sold within various countries of
https://www.desitinpharma.com/about-desitin/the-company/company-profile/
The German company,
https://www.fresenius.com/worldwide
Fresenius is a global healthcare group offering high-quality products and services for dialysis, hospitals, and outpatient treatment. With over 290,000 employees in more than 100 countries around the globe, and annual sales exceeding €35 billion, Fresenius is one of the world's leading healthcare companies.
is the world leader in treating people with chronic kidney failure.
Fresenius Helios
is
Fresenius Kabi
supplies essential drugs, clinical nutrition products, medical devices and services to help critically and chronically ill patients, while
Fresenius Vamed
plans, develops and manages healthcare facilities.
At Fresenius, the patient always comes first. For more than 100 years now we have been working to save lives and improve the quality of life of our patients. A clear focus on innovation and efficiency has helped us to make high-quality healthcare accessible to a steadily increasing number of people. Yet we never get complacent about our successes, and never stop looking for better solutions. This is how Fresenius is contributing to medical progress and better patient care.
Success in our business is the key for investing in high-quality yet affordable healthcare. In this way we are meeting our social responsibility to help patients, while ensuring that Fresenius remains successful over the long term.
Fresenius leads by recognizing important trends and developments early, then working with our partners to help shape healthcare systems. Aging populations and the expansion of healthcare provision in countries worldwide are driving demand for medical products and services, and Fresenius is excellently positioned to continue our strong growth into the future.
At Fresenius, "
https://www.fresenius.com/Group-Overview
Revenue growth of 5% in 2023 driven by favorable business development
Operating income 1 growth of 15% exceeding top end of outlook range, due to business growth, FME25 savings ahead of plan and contributions from the Tricare settlement
Successful execution on turnaround plan resulting in significant labor productivity improvements in Care Delivery and positive pricing in Care Enablement
Several key divestments announced as part of the ongoing Portfolio Optimization Program
Strong cash flow performance and net financial leverage ratio reduced
Dividend of €1.19 per share proposed
For 2024 continued revenue growth and accelerated operating income growth projected
Key figures (IFRS)
Q4 2023 EUR m
Q4 2022 EUR m
Growth yoy
Growth yoy, cc
FY 2023 EUR m
FY 2022 EUR m
Growth yoy
Growth yoy, cc
Revenue
4,988
4,997
0%
+7%
19,454
19,398
0%
+5%
Operating income excl. special items and PRF 1
428 555
352 489
+22% +14%
+27% +18%
1,369 1,741
1,512 1,540
-9% +13%
-7% +15%
Net income 2 excl. special items and PRF 1
188 259
139 248
+35% +4%
+41% +8%
499 756
673 729
-26% +4%
-24% +6%
Basic EPS (EUR) excl. special items, and PRF 1
0.64 0.88
0.47 0.85
+35% +4%
+41% +8%
1.70 2.58
2.30 2.49
-26% +4%
-24% +6%
yoy = year-on-year, cc = at constant currency, EPS = earnings per share
Successful execution against the strategic plan
Structure: During fiscal year 2023,
Operational efficiency: In 2023, the company successfully executed on its operational efficiency improvement and turnaround plans. The FME25 transformation program reached annual sustainable savings of
Portfolio Optimization:
Capital Allocation: During 2023,
Sustainability:
Revenue development driven by solid organic growth
In the fourth quarter 2023, revenue remained flat with
Care Delivery revenue remained flat with
In Care Delivery
In
Care Enablement revenue declined slightly by 1% to
Within Inter-segment eliminations 3 , revenue for products transferred between the operating segments at fair market value declined by 5% to
In full year 2023 , revenue was stable at
Earnings development driven by labor productivity improvements and FME25 savings
In the fourth quarter 2023, operating income increased by 22% to
Operating income in Care Delivery rose by 13% to
Operating income in Care Enablement amounted to
Operating income for Corporate amounted to
In the full year 2023 , operating income decreased by 9% to
Net income 2 increased by 35% to
In the full year 2023, net income 2 declined by 26% to
Basic earnings per share (EPS) increased by 35% to
In the full year 2023, EPS declined by 26% to
Strong cash flow development
Free cash flow 4 increased by 21% to
Patients, clinics and employees
As of
Outlook 5
In 2024,
The Company expects operating income to grow by a mid- to high-teens percent rate compared to prior year.
The expected growth rates for 2024 are at constant currency, excluding special items. The 2023 basis for the revenue outlook is
The Company reconfirms its targets to achieve an operating income margin of 10% to 14% by 2025. This excludes impacts from portfolio changes.
https://www.freseniusmedicalcare.com/en/news/q4-2023
Grünenthal
The German company, Grünenthal
https://www.grunenthal.com/en/about-us/global-capabilities
Grünenthal is a global leader in pain management. Our purpose is to change lives for the better - and innovation is our passion. We're driven to seek effective, life-changing medicines and solutions for patients with severe diseases and high unmet medical needs. We are focussing all of our activities and efforts on moving towards our vision of a world free of pain.
As a science-based, privately-owned pharmaceutical company, we have a long track record of bringing innovative treatments and state-of-the-art technologies to people living with pain worldwide. Strong ongoing partnerships with leading healthcare and development organisations bring our new products to life. We're a fully integrated pharmaceutical company that offers support along the entire value chain - from drug development through to commercialisation.
Grünenthal is headquartered in
https://www.grunenthal.com/en/about-us
Grünenthal reports record revenue and profit in 2022 full-year results and strong pipeline progress
In 2022, Grünenthal generated €1.7 billion in revenues, an increase of 13 percent over prior year.
Adjusted EBITDA increased by 18 percent to €438 million and more than tripled since 2017.
Substantial pipeline advancement with two late-stage development projects in osteoarthritis and post-surgical neuropathic pain and two projects in early development focused on chronic pain and inflammatory diseases.
M&A highlights include the acquisition of Nebido™ from Bayer and the joint venture agreement with
The company exceeded its financial and non-financial targets, progressing on its growth path. Net revenues reached €1.7 billion, an increase of 13 percent compared to 2021. The adjusted EBITDA reached €438 million, an increase of 18 percent over 2021, and more than tripled since 2017. Grünenthal has also more than tripled its operating cash flow since 2017, positioning the company well to further invest in advancing the R&D pipeline, continuing the M&A strategy, and growing the business in
The 2022 results were driven by excellent business performance and revenues from strategic partnerships. Key brands such as Qutenza™, Palexia™, Vimovo™, and Zomig™ performed well and grew faster than the market. Qutenza™, a topical non-opioid treatment for various neuropathic pain conditions, saw a surge in demand, particularly in the
"Grünenthal's exceptional performance in 2022 is a testament to our people and reflects the demand for better pain treatments," says
In 2022, Grünenthal further advanced the investigational medicines in its research pipeline. A key priority is the development of Resiniferatoxin (RTX). The investigational treatment is being developed for treating pain in patients with knee osteoarthritis and entered clinical phase III in
Grünenthal's second phase III programme investigates the use of Qutenza™ in patients with post-surgical neuropathic pain (PSNP) to support an extension of the
In phase I, trials are ongoing for a Nociceptin/Orphanin FQ peptide receptor (NOP) agonist. The compound is being developed to provide a non-opioid therapy option with a strong analgesic effect without the side effects commonly associated with opioids. Grünenthal also further develops its Glucocorticoid Receptor Modulator (GRM) in Phase I. The oral investigational medicine aims to provide a therapy option with broad anti-inflammatory efficacy and a more favourable benefit-risk profile than current glucocorticoid-based therapies like prednisolone.
In
In addition to serving patients suffering from pain, Grünenthal aims to positively impact its employees, partners, and society - while reducing the environmental footprint of its business activities. Grünenthal is a recognised leader in Environment, Social and Governance (ESG) in its industry. In
Driving a high-performance culture is key to Grünenthal's success. Following excellent employee engagement scores during the 2022 survey, Grünenthal has 24 entities worldwide certified as a
About Grünenthal
Grünenthal is a global leader in pain management and related diseases. As a science-based, privately-owned pharmaceutical company, we have a long track record of bringing innovative treatments and state-of-the-art technologies to patients worldwide. Our purpose is to change lives for the better, and innovation is our passion. We are focusing all our activities and efforts on working towards our vision of a world free of pain.
Grünenthal is headquartered in
https://www.grunenthal.com/en/press-room/press-releases/2023/2022-full-year-result-gruenenthal
The parent company of the global
The HARTMANN GROUP is one of
We have offices in 36 countries around the world, but our products are available in over 130 countries through a network of distributors.
In a world where health is becoming an increasingly important matter and is managed more professionally, we offer our customers simple and effective solutions for the benefit of the patients. We are ambitious and constantly looking for ways to improve outcomes in both the professional sector and at home. This is expressed in our brand promise of "Helps. Cares. Protects". Our core portfolio is augmented by consumer-based medical ranges, along with care products and cosmetics.
In 2021, we employed 10,628 staff worldwide and generated sales of
https://www.hartmann.info/en-corp/whoweare
Strongly increased earnings forecast for 2023 at
Market and purchasing conditions continue to have a strong impact
Earnings forecast for 2023 raised significantly to
January to
Organic sales growth of 2.5%
Sales increase due to necessary price adjustments
Adjusted EBITDA increased due to successful implementation of cost measures, earnings level still impacted by crises
Heidenheim,
The Company generated adjusted EBITDA of
The Company recorded positive sales growth in Incontinence Management and Wound Care. In contrast, demand in Infection Management fell due to a further decline in the markets for protective clothing and disinfection products in particular. The Group's Complementary Divisions recorded moderate organic sales growth overall.
The Company improved its net financial status by around
Outlook 2023
In 2023, HARTMANN launched innovative products on the market and implemented projects with substantial cost improvements. Despite a slight recovery, the additional costs for materials, energy and transport for 2023 alone are in the very high double-digit million euro range. Market conditions remain difficult, such as reduced demand markets and structural cost increases, e. g. due to higher wages.
"Our Transformation Program will contribute just under
Based on the business performance to date in 2023 and current forecasts for the business outlook, HARTMANN expects to strongly exceed the previously planned earnings level for 2023 and thus slightly above the previous year's level. The Company currently anticipates adjusted EBITDA of
https://www.hartmann.info/en-corp/articles/7/4/press-release-q3-2023
As a vibrant science and technology company, we believe in science as a force for good. We make a positive difference in millions of people's lives. Discover how Merck uses science to drive human progress!
Our passion for science and technology is what drives our 62,770 employees across 66 countries to find solutions to some of today's toughest challenges and create more sustainable ways to live.
We are here for people at every step, helping create, improve and prolong life. We deliver personalized treatments for serious diseases and enable people to achieve their dream of becoming parents. We empower the scientific community. Our tools, services, and digital platform make research simpler, more exact, and help to deliver breakthroughs more quickly. We provide progressive treatment solutions that help improve access to health thanks to the accuracy of our tests and the reliability of our medicine. As a company, we are at the forefront of digital living. Our science sits inside technologies that change the way we access, store, process, and display information. Our innovative technology drives human progress and opens new possibilities to transform life on Earth as we know it.
Thanks to the constant curiosity of our employees, we are making discoveries that can change the landscape of entire industries. For more than 350 years, we've been pushing the boundaries of what's possible, and we'll continue to do so in the years to come.
https://www.merckgroup.com/en/company.html
Merck to Return to Growth during Fiscal 2024
Merck expects to return to growth during fiscal 2024. This was announced by the company at today's Capital Markets Day.
Transitional year 2023 managed well so far thanks to resilient business model
Medium-term growth targets confirmed
Merck expects continued growth also beyond 2025
Geographical footprint: Close to customers with a diversified position in the economically most important regions
Merck, a leading science and technology company, expects to return to growth during fiscal 2024. This was announced by the company at today's Capital Markets Day. In addition, Merck confirmed its medium-term growth targets for its three business sectors and expects continued growth beyond 2025.
Thanks to its set-up with three business sectors, Merck expects to see on average stable sales in fiscal 2023, despite a difficult market environment in Life Science and Electronics. The company still assumes an organic sales development of −2% to +2%, leading to net sales of € 20.5 billion to € 21.9 billion in total. In the first half of 2023, the strong growth of Healthcare largely offset the organic sales declines in Life Science and Electronics.
In fiscal 2024, Merck expects to return to organic sales growth for the Group. Several factors will contribute to this: In the Life Science business sector, the decline in Covid-19-related sales will be lower than in fiscal 2023. In the Process Solutions business unit, inventory destocking by key customers should end in early 2024, with sales starting to pick up again during the first half of the year. In Healthcare, Merck expects growth to normalize in line with medium-term aspirations. The market for semiconductor materials in the Electronics business sector is also assumed to recover incrementally in 2024.
At its Capital Markets Day, Merck confirmed its medium-term growth targets for its three business sectors. The company expects the following compound annual growth rates for organic sales development:
Life Science: 7% to 10%
Healthcare: mid-single digit percentage range
Electronics: 3% to 6%
Merck attributes this confidence in its medium-term growth potential also beyond 2025 to an optimal positioning: With its diversified portfolio, the company benefits from key megatrends. In the Life Science business sector, this includes the growing market for complex and novel modalities such as viral vectors, antibody-drug conjugates and
mRNA
.
In the Healthcare business sector, Merck develops and commercializes specialty pharmaceuticals for oncology and neurology, among others. These include the medicines Bavencio (cancer) and Mavenclad (multiple sclerosis), both of which have shown strong growth in the first half of fiscal 2023. In addition, Merck is conducting clinical trials with the pipeline assets xevinapant (head and neck cancer) as well as evobrutinib (multiple sclerosis).
With its industry-leading range of semiconductor materials, the Electronics business sector expects positive growth impetus in the medium term from the further implementation of artificial intelligence and the Internet of Things (IoT).
With regards to its geographic footprint, Merck aims to be close to local customers with an established position in the economically most important world regions. For instance, in fiscal 2022, the company generated around 35% of its sales in the
, this region was responsible for around 35% of global gross domestic product (GDP) in 2022. Merck is also well-positioned in other key regions. In fiscal 2022, the company generated around 29% of sales in
Through its global footprint, Merck is also increasing its resilience and becoming less dependent on individual markets, segments and regions.
https://www.merckgroup.com/en/news/capital-markets-day-19-10-2023.html
The parent of the global
In
https://www.merz.com/blog/news/merz-to-create-three-independent-customer-focused/
Merz is a global, diversified healthcare company based in
Merz is a privately held pharmaceutical company based in
https://www.merz.com/about-merz/facts-figures/
Merz is a global, family-owned aesthetics and neurotoxin company inspired by more than 110 years of innovation, commitment and trust. Driven by the opportunity to help people look better, feel better and live better, Merz earns the confidence of clinicians in aesthetics and neuroscience with a relentless focus on customer service to providers and overall satisfaction for patients.
As a family-owned company, Merz values personal relationships; we recognize that our obligation is to understand the needs of our physician customers, so we can help them best serve their patients. You see it in how we engage with our customers in every aspect of our business. You see it in our holistic portfolio of products. And you'll see it in the innovations that are already expanding that portfolio.
From our scientific expertise developed over more than a century, to our focus on customer needs, the Merz way means your success is our success.
https://www.merz.com/about-merz/
https://www.morphosys.com/company
MorphoSys AG Reports First Nine Months and Third Quarter 2023 Financial Results
Phase 3 MANIFEST-2 topline results expected by the end of November, with detailed findings in oral presentation at ASH 2023
Monjuvi®
€ 642.2 million in cash and other financial assets as of
Conference call and webcast (in English) tomorrow,
"With pelabresib,
Monjuvi/Minjuvi ® Highlights:
Monjuvi (tafasitamab-cxix)
Minjuvi royalty revenue of € 1.2 million for sales outside of the
Conference Highlights:
Topline results from the Phase 3 MANIFEST-2 trial of pelabresib, an investigational
Following the release of the topline MANIFEST-2 study results, detailed findings from the study will be presented during an oral session on
Beyond the MANIFEST-2 study, seven additional abstracts on pelabresib and tafasitamab were accepted for presentation and publication at ASH 2023.
Tulmimetostat Highlight:
In
Events After the End of the Third Quarter of 2023:
Financial Results for the Third Quarter of 2023 (IFRS):
Total revenues for the third quarter 2023 were € 63.8 million compared to € 95.8 million for the same period in 2022. The decrease resulted from lower revenues from licenses compared to prior year.
in € million*
Q3 2023
Q2 2023
Q3 2022
Q-Q Δ
Y-Y Δ
Total revenues
63.8
53.2
95.8
20 %
(33) %
Monjuvi product sales
21.5
21.7
21.9
(1) %
(2) %
Royalties
34.0
26.8
29.7
27 %
14 %
Licenses, milestones and other
8.3
4.6
44.1
80 %
(81) %
* Differences due to rounding.
Cost of Sales: In the third quarter of 2023, cost of sales was € 15.1 million compared to € 8.1 million for the comparable period in 2022.
Research and Development (R&D) Expenses: In the third quarter 2023, R&D expenses were € 63.2 million (Q3 2022: € 77.8 million). The decrease mainly resulted from lower expenses for external services.
Selling, General and Administrative (SG&A) Expenses: Selling expenses in the third quarter 2023 were € 19.9 million (Q3 2022: € 23.5 million). The selling expenses decreased due to streamlining and focusing of selling efforts. General and administrative (G&A) expenses amounted to € 15.0 million (Q3 2022: € 15.6 million).
Impairment of
Operating Loss: Operating loss amounted to € 51.0 million in the third quarter 2023 (Q3 2022: operating loss of € 29.3 million).
Consolidated Net Loss: For the third quarter 2023, consolidated net loss was € 119.6 million (Q3 2022: consolidated net loss of € 122.9 million).
Financial Results for the first nine months 2023 (IFRS):
Revenues for the first nine months of 2023 were € 179.3 million (9M 2022: € 196.7 million). The decrease resulted from lower revenues from licenses compared to prior year. Revenues include € 62.6 million from the recognition of Monjuvi product sales in the
in € million*
9M 2023
9M 2022
Y-Y Δ
Total revenues
179.3
196.7
(9) %
Monjuvi product sales
62.6
60.2
4 %
Royalties
82.4
70.8
16 %
Licenses, milestones and other
34.2
65.6
(48) %
* Differences due to rounding.
Cost of Sales: For the first nine months of 2023, cost of sales were € 43.8 million compared to € 33.2 million in 2022. The increase was primarily driven by higher sales of Monjuvi in the
R&D Expenses: In the first nine months of 2023, R&D expenses were € 203.3 million compared to € 203.8 million in 2022.
SG&A Expenses: Selling expenses decreased in the first nine months of 2023 to € 58.8 million compared to € 69.4 million in 2022. The selling expenses decreased due to streamlining and focusing of selling efforts. G&A expenses amounted to € 42.9 million compared to € 42.6 million in the first nine months of 2022.
Impairment of
Operating Loss: Operating loss amounted to € 171.1 million in the first nine months of 2023 compared to an operating loss of € 152.3 million in 2022.
Consolidated Net Loss: For the first nine months of 2023, consolidated net loss was € 238.0 million compared to a net loss of € 480.5 million in 2022.
Cash and Other Financial Assets: As of
Number of shares: The number of shares issued totaled 34,231,943 on
Updated Full Year 2023 Financial Guidance:
The updated financial guidance was issued on
Updated 2023 Financial Guidance
Previous 2023 Financial Guidance*
2023 Guidance Insights
Monjuvi
US$
100% of Monjuvi
Gross margin for Monjuvi
Approx. 75%
75% to 80%
100% of Monjuvi
R&D expenses
€ 290m to 315m
€ 290m to 315m
2023 anticipated to be incrementally higher than 2022 due to the expansion of the pelabresib development program.
SG&A expenses
€ 140m to 155m
€ 140m to 155m
45% to 50% of mid-point of SG&A expenses represent Monjuvi
*The Previous Financial Guidance 2023 was initially provided on
Additional information related to 2023 Financial Guidance:
Tremfya ® royalties will continue to be recorded as revenue without any cost of sales in
Operational Outlook:
The following events and development activities are upcoming and planned for 2024 and beyond:
Topline results for the pivotal Phase 3 study (MANIFEST-2) of pelabresib in myelofibrosis (MF) are expected by the end of November;
Primary analysis data from the Phase 3 study (inMIND) of tafasitamab in patients with indolent lymphoma (r/r FL/MZL) in 2024;
Primary analysis data from the pivotal Phase 3 study (frontMIND) of tafasitamab in previously untreated DLBCL in the second half of 2025.
MorphoSys Group
in € million
Q3 2023
Q3 2022
Δ
9M 2023
9M 2022
Δ
Revenues
63.8
95.8
(33) %
179.3
196.7
(9) %
Product Sales
21.5
21.9
(2) %
62.6
60.2
4 %
Royalties
34.0
29.7
14 %
82.4
70.8
16 %
Licenses, Milestones and Other
8.3
44.1
(81) %
34.2
65.6
(48) %
Cost of Sales
(15.1)
(8.1)
86 %
(43.8)
(33.2)
32 %
Gross Profit
48.7
87.7
(44) %
135.5
163.5
(17) %
Total Operating Expenses
(99.7)
(117.0)
(15) %
(306.6)
(315.8)
(3) %
Research and Development
(63.2)
(77.8)
(19) %
(203.3)
(203.8)
0 %
Selling
(19.9)
(23.5)
(15) %
(58.8)
(69.4)
(15) %
General and Administrative
(15.0)
(15.6)
(4) %
(42.9)
(42.6)
1 %
Impairment of
(1.6)
—
n/a
(1.6)
—
n/a
Operating Profit / (Loss)
(51.0)
(29.3)
74 %
(171.1)
(152.3)
12 %
Other Income
2.1
10.6
(80) %
4.9
19.8
(75) %
Other Expenses
(0.8)
(7.5)
(89) %
(3.1)
(23.0)
(87) %
Finance Income
(22.5)
70.3
>(100)%
39.1
87.1
(55) %
Finance Expenses
(44.6)
(167.5)
(73) %
(101.2)
(415.4)
(76) %
Income from Reversals of Impairment Losses / (Impairment Losses) on Financial Assets
0.0
0.6
(100) %
0.6
(0.4)
>(100)%
Share of Loss of Associates accounted for using the Equity Method
(2.3)
(0.3)
>100%
(6.6)
(0.3)
>100%
Income Tax Benefit / (Expenses)
(0.5)
0.1
>(100)%
(0.5)
4.1
>(100)%
Consolidated Net Profit / (Loss)
(119.6)
(122.9)
(3) %
(238.0)
(480.5)
(50) %
Earnings per Share, Basic and Diluted (in €)
(3.50)
(3.60)
(3) %
(6.97)
(14.07)
(50) %
Cash and other financial assets (end of period)
642.2
907.2 *
(29) %
642.2
907.2 *
(29) %
* Value as of
Rhön-
RHÖN‐KLINIKUM AG is one of the largest healthcare providers in
https://en.rhoen-klinikum-ag.com/
RHÖN-KLINIKUM AG publishes result for first half of 2023 - outlook confirmed
RHÖN-KLINIKUM AG closed the first half of 2023 with a 2.4 per cent increase in revenues to
At
The key figures of the first six months are influenced by two main developments: on the one hand, by the still persisting inflation, coping with the impacts of higher energy and commodity prices, as well as the geopolitical risks brought about by the war in
Now that UKGM and the trade union ver.di on
This will enable us to seize the opportunities arising from an agreement signed at the end of
Outlook
For the current financial year 2023 we continue to expect revenues of
The outlook is further subject to considerable uncertainties in connection with the geopolitical risks brought about by the war in
The parent of the global
Worldwide,
https://www.stada.com/about-stada/stada-worldwide
At
https://www.stada.com/about-stada/who-we-are
Double-digit growth journey continues with 16% sales increase to €2.1bn 1 and 30% EBITDA to €509 million 1 in first six months of 2023
Organic growth in
Bad Vilbel -
Group sales increased by 16% to €2.1 billion 1 while earnings (EBITDA) improved by 30% to €509 million 1 in the first six months of 2023. H1 is another proof point for
"
CEO,
Major milestones achieved in supporting patient access to medicines
During the first half of 2023,
Through initiatives such as photovoltaic cells in
In September the group will also unveil the results of its 2023 STADA Health Report - the ninth since publication began. This unique survey with more than 32,000 participants across 16 countries will provide valuable insights into the physical and mental health and wellbeing of the population. In doing so,
Three strategic business segments drive consistent growth
In the area of
In the field of Generics, launches including the anticoagulant apixaban in countries such as the
Specialty sales are ahead by 24% on an adjusted basis to €432.1 million in the first half of this year and made up 21% of group sales. During the first half of 2023,
A further milestone was reached in that more than 1,000 patients are now being treated with
Strong basis for consistent, sustainable growth
The group can build on strong capabilities in small-molecule development enabling cost leadership and is generally agnostic as to whether these products are developed externally or internally. In fact, one of the benefits of commercial agility is that the group can close attractive product deals more easily being a partner of choice for
"
Global Banking 6 Mar 24 – INDUSTRY SNAPSHOTS
France Banking 5 Mar 24 – INDUSTRY SNAPSHOTS
Advisor News
- Economy showing momentum despite uncertainty
- 7 ways financial advisors can benefit by giving back to nonprofits
- Emergency Preparedness: How advisors can prepare clients for hurricanes
- Federal employees: An emerging market for advisors
- The financial advisor’s guide to creating an effective value proposition
More Advisor NewsAnnuity News
Health/Employee Benefits News
- Medicaid overhaul proves to be politically perilous proposition
- Worries persist about CVS Health
- Cigna commercial health plans may go out-of-network at large local hospital group
- The Medicaid Asset Protection Trust (MAPT)
- Lawmaker seeks coverage for menopause
More Health/Employee Benefits NewsLife Insurance News
- AM Best Places Credit Ratings of Banner Life Insurance Company and William Penn Life Insurance Company of New York Under Review With Developing Implications
- Best's Review Examines Value in Innovation Culture
- Initial Registration Statement for Employee Benefit Plan (Form S-8)
- Securian Financial Enhances Its Flagship Indexed Universal Life Insurance Product
- AM Best Affirms Credit Ratings of The Dai-ichi Life Insurance Company, Limited
More Life Insurance News